Drug intelligence / Profile preview

ASP4901

Development stage: Phase 2
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP4901 is a small molecule inhibitor of phosphodiesterase 9A (PDE9A), developed for the treatment of benign prostatic hyperplasia (BPH). The drug was evaluated in phase 2 clinical trials to assess its efficacy and safety in patients with BPH. The mechanism of action involves inhibition of PDE9A, an enzyme that regulates cyclic guanosine monophosphate (cGMP) levels, which may influence smooth muscle tone and urinary symptoms associated with BPH. Development was led by Astellas Pharma and ASKA Pharmaceutical[5][6][3].

Targets

PDE9A (Phosphodiesterase 9A)

Beyond the preview

Go deeper on ASP4901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP4901.

Explore the full profile